The role of insulin-like growth factors and their binding proteins in tumor hypoglycemia

Hormone Research in Paediatrics

Volumn 46, Issue 4-5, 1996, Pages 195-201

  Baxter, Robert C ^a  

^a ROYAL NORTH SHORE HOSPITAL   (Australia)

Author keywords

Binding protein; Glucocorticoids; Growth hormone; Hypoglycemia; Insulin like growth factor; Nonpancreatic tumors

Indexed keywords

CORTICOSTEROID; GLUCOCORTICOID; GROWTH HORMONE; INSULIN; PROTEIN SUBUNIT; SOMATOMEDIN; SOMATOMEDIN B; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN BINDING PROTEIN 2; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN BINDING PROTEIN 6; SOMATOMEDIN C;

COMPLEX FORMATION; CONFERENCE PAPER; CONTROLLED STUDY; CORTICOSTEROID THERAPY; HUMAN; HYPOGLYCEMIA; INSULIN BLOOD LEVEL; MESENCHYMOMA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN GLYCOSYLATION; PROTEIN SECRETION; TUMOR;

HUMANS; HYPOGLYCEMIA; INSULIN; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; INSULIN-LIKE GROWTH FACTOR I; INSULIN-LIKE GROWTH FACTOR II; NEOPLASMS;

EID: 0029797354     PISSN: 16632818     EISSN: 16632826     Source Type: Journal    
DOI: 10.1159/000185023     Document Type: Article

References (41)

1. Baxter RC: Circulating binding proteins for the insulin-like growth factors, Trends Endocrinol Metab 1993;4:91-96.
2. Megyesi K, Kahn CR, Roth J, Gorden P: Hypoglycemia in association with cxtrapancrcatic tumors: Demonstration of elevated plasma NSlLA-s by a new radioreceptor assay, J Clin Endocrinol Metab 1974:38:931-934.
3. Kahn CR: The riddle of tumour hypoglycacmia revisited, Clin Endocrinol Metab 1980:9:335-360.
4. Widmer U, Zapf J, Frocsch ER: Is cxtrapancrcatic tumor hypoglycemia associated with elevated levels of insulin-like growth factor II? J Clin Endocrinol Metab 1982:55:833-839.
5. Merimcc TJ: Insulin-like growth factors in patients with nonislct cell tumors and hypoglycemia, Metab Clin Exp 1986:35:360-363.
6. Daughaday WH, Trivcdi B, Baxter RC: Abnormal serum IGF-II transport in non-islet cell tumor hypoglycemia results from abnormalities of both IGF binding protein-3 and acid-labile subunit and leads to elevation of serum free IGF-II, Endocrine 1995:3:425-428.
7. Teale JD, Marks V: inappropriately elevated plasma insulin-like growth factor II in relation to suppressed insulin-like growth factor I in the diagnosis of non-islet cell tumour hypoglycacmia, Clin Endocrinol 1990;33:87-98.
8. Cotterill AM, Holly JM, Davies SC, Coulson VJ, Price PA, Wass JA: The insulin-like growth factors and their binding proteins in a case of non-islet-ccll tumour-associated hypoglycae-mia, J Endocrinol 1991;131:303-311.
9. Wing JR, Panz VR, Joffe BI, Kalk WJ, Seftel HC, Zapf J, Kew MC: Hypoglycemia in hepatocellular carcinoma: Failure of short-term growth hormone administration to reduce enhanced glucose requirements, Metab Clin Exp 1991;40:508-512.
10. Eastman RC, Carson RE, Orloff DG, Cochran CS, Perdue JF, Rechler MM, Lanau F, Roberts CT, Shapiro J, Roth J, LeRoith D: Glucose utilization in a patient with hepatoma and hypoglycemia: Assessment by a positron emission tomographv, J Clin Invest 1992;89:1958-1963.
11. Daughaday WH, Emanuclc MA, Brooks MH, Barbato AL, Kapadia M, Rotwein P: Synthesis and secretion of insulin-like growth factor II by a leiomyosarcoma with associated hypoglycemia, N Engl J Med 1988:319:1434-1440.
12. Schofield PH, Connor H, Turner RC, Zapf J: Tumour hypoglycaemia: Raised tumour 1GFI1 mRNA associated with reduced plasma Somatomedins, Br J Cancer 1989:60:661-663.
13. Shapiro ET, Bell GL, Polonsky KS, Rubenstein AH, Kew MC, Tager HS: Tumor hypoglycemia: Relationship to high molecular weight insulin-like growth factor-II, J Clin Invest 1990; 85:1672-1679.
14. Zapf J, Futo E, Peter M, Frocsch ER: Can 'big' insulin-like growth factor II in serum of tumor patients account for the development of extra-pancreatic tumor hypoglycemia? J Clin Invest 1992;90:2574-2584.
15. Daughaday WH, Trivedi B: Heterogeneity of scrum peptides with immunoactivity detected by a radioimmunoassay for proinsulin-like growth factor-11 E domain: Description of a free E domain peptide in serum, J Clin Endocrinol Metab 1992;75:641-645.
16. Daughaday WH, Trivedi B, Baxter RC: Serum ‘big insulin-like growth factor IF from patients with tumor hypoglycemia lacks normal E-do-mair, O-Iinked glvcosylation, a possible determinant of normal propeptide processing, Proc Natl Acad Sci USA 1993;90:5823-5827.
17. Liu F, Baker BK, Powell DR, Hintz RL: Characterization of proinsulin-like growth factor-11 E-region immunorcactivity in serum and other biological fluids, J Clin Endocrinol Metab 1993;76:1095-1100.
18. Perdue JF, Gowan LK, Hudgins WR, Scheuermann J, Foster B, Brown SN: Development of a specific radioimmunoassay for E domain containing forms of insulin-like growth factor II, Adv Exp Med Biol 1991:293:45-56.
19. Tally M, Eriksson U, Thoren M, Brismar K, Hall K: Immunoreaclivc proinsulin-likc growth factor-ll levels in healthy subjects, patients with growth hormone deficiency, and patientswith type 1 diabetes: Effects of insulinlike growth factor-I and insulin, J Clin Endocrinol Mctab 1994:79:1576-1581.
20. Daughaday WH, Kapadia M: Significance of abnormal serum binding of insulin-like grow th factor II in the development of hypoglycemia in patients with non-islet-cell tumors, Proe Natl Acad Sci USA 1989;86:6778-6782.
21. Baxter RC, Daughaday WH: Impaired formation of the ternary insulin-like growth factor-binding protein complex in patients with hypoglycemia due to nonislct cell tumors, J Clin Endocrinol Metab 1991:73:696-702.
22. Baxter RC: Circulating levels and molecular distribution of the acid-labile (u) subunit of the high molecular weight insulin-like growth factor-binding protein complex, J Clin Endocrinol Metab 1990:70:1347-1353.
23. Baxter RC, Holman SR, Corbould A, Stranks S, Ho PJ, Braund W: Regulation of the insulinlike growth factors and their binding proteins by glucocorticoid and growth hormone in nonislct cell tumor hypoglycemia, J Clin Endocrinol Metab 1995;80:2700-2708.
24. Giudicc EC: IGF binding protein-3 protcase regulation: How sweet it is, J Clin Endocrinol Mctab 1995:80:2279-2281.
25. Baxter RC, Bayne ML, Cascieri MA: Structural determinants for binary and ternary complex formation between insulin-like growth faetor-l (IGF-1) and IGF binding protein-3, J Biol Chem 1992;267:60-65.
26. Tannenbaum GS, Guyda HJ, Posner BI: Insulin-like growth factors: A role in growth hormone negative feedback and body weight regulation via brain, Science 1983:220:77-79.
27. Schofield PN, Granerus M, Tally M, Engst rom W: The biological effects of a high molecular weight form of IGF II in a pluripotent human teratocarcinoma cell line, Anticancer Res 1994; 14:533-538.
28. Gowan LK, Hampton B, Hill DJ, Schlueter RJ, Perdue JF: Purification and characterization of a unique high molecular weight form of insulin-like growth factor II, Endocrinology 1987; 121: 449-458.
29. Bar RS, Clemmons DR, Boes M, Busby WH, Booth BA, Dake BL, Sandra A: Transcapillary permeability and subendothclial distribution of endothelial and amniotic fluid insulin-like growth factor binding proteins in the rat heart, Endocrinology 1990; 127:1078-1086.
30. Zapf J, Schmid C, Waldvogel M, Mauri C, Futo E, Hossenlopp P, Binoux M, Froesch FR: Regulation of binding proteins for insulin-like growth factors (IGF) in humans, J Clin Invest 1990:86:952-961.
31. Blum WF, Horn N, Kratzsch J, Jorgensen JOL, Juul A, Teale D, Mohnike K, Ranke MB: Clinical studies of IGFBP-2 by radioimmunoassay, Growth Regul 1993;3:100-104.
32. Baxter RC, Saunders H: Radioimmunoassay of insulin-like growth factor binding protein-6 in human serum and other body fluids, J Endocrinol 1992;34:133-139.
33. Binder C, Bcndlson 1: Endocrine emergencies: Hypoglvcaemia, Clin Endocrinol Mctab 1992; 6:23-39.
34. Nesbitt KA, Boswell JT, Gonzales MA, Sarkisian SS: Malignant mesothelioma associated with hypoglycemia, Am J Clin Pathol 1958:30: 148-157.
35. Foger B, Zapf J, Lechleitner M, Konwalinka G, Patsch JR: Prevention with glucocorticoids of extrapancrcatic tumour-hypoglycaemia as a result of increased ‘big’ insulin-like growth factor II, J Intern Med 1994;236:692-693.
36. Teale JD, Blum WF, Marks V: Alleviation of non-islet cell tumour hvpoglycycmia by growth hormone therapy is associated with changes in IGF binding protein-3, Ann Clin Biochcm 1992;29:314-323.
37. Agus MS, Katz LE, Satin SM, Meadows AT, Hintz RL, Cohen P: Non-islet-cell tumor associated with hypoglycemia in a child: Successful long-term therapy with growth hormone, J Pc-diatr 1995;127:403-407.
38. Teale JD, Baxter RC, Marks V: Therapeutic GH increases 1GFBP-3 ternary complex formation in cases of non-islet cell tumour hypo-glycaemia, J Endocrinol 1993;137(suppl):P53.
39. Rizza RA, Mandarino L, Gerich JE: Cortisol-induced insulin resistance in man: Impaired suppression of glucose production and stimulation of glucose utilization due to a postrcceptor defect in insulin action, J Clin Endocrinol Mctab 1981;54:131-138.
40. Rizza RA, Cryer PE, Gerich JE: Role of glucagon, epinephrine and growth hormone in human glucose countcrrcgulation: ElTccts of somatostatin and adrenergic blockade on plasma glucose recovery and glucose flux rates following insulin induced hypoglycemia, J Clin Invest 1979;64:62-71.
41. Ron D, Powers AC, Pandian MR, Godine JE, Axelrod L: Incresed insulin-like growth factor II production and consequent suppression of growth hormone secretion: A dual mechanism for tumor-induced hypoglycemia, J Clin Endocrinol Metab 1989;68:701-706.